Page 40 - Zymeworks Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Canadian Biotech Venture Capital Firm Lumira Starts Hedge Fund to Target Oversold Public Companies. Vancouver, BC, September 19, 2022--Lumira Ventures, one of Canada's top investors in private health sciences startups, is launching a hedge fund to bet on publicly traded companies it believes have been oversold during the sector's meltdown in the past year. Lumira has previously raised four venture capital funds to invest in private health sciences companies - including its latest, a US$223-million fund last year that was the largest in Canada in two decades - and backed some of the top Canadia...

16.09.2022 - Zymeworks Inc. (“Zymeworks” or the “Company”) (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that independent proxy advisory firm Glass, Lewis & Co. (“Glass Lewis”) has ... Seite 1

Redomicile anticipated to enhance long-term value for securityholders, provide opportunities for increased value of Zymeworks common shares, and better position the Company for future growthZymeworks Board recommends that Zymeworks securityholders vote FOR the Redomicile resolutionTo vote, contact Kingsdale Advisors...

Redomicile anticipated to enhance long-term value for securityholders, provide opportunities for increased value of Zymeworks common shares, and better position the Company for future... | September 8, 2022

Zanidatamab zovodotin shown to have manageable safety profile with encouraging, single-agent anti-tumor activity in patients with HER2+ cancers Results to be reviewed in an oral presentation